Anixa Biosciences announced successful Phase 1 results for its breast cancer vaccine, achieving all primary endpoints and immune responses in 74% of participants, with Phase 2 preparations underway. Their ovarian cancer CAR-T therapy, lira-cel, has reached the highest dose level in its ongoing Phase 1 trial, showing no dose-limiting toxicities and extended survival beyond one year in four patients. These advancements highlight Anixa's progress in cancer immunotherapy, supported by collaborations with Cleveland Clinic and Moffitt Cancer Center. The company will present these updates at the 2026 Cantor Fitzgerald Global Healthcare Conference.
Okta reported better-than-expected Q1 results with EPS of $1.05 and revenue of $805 million, driven by high demand for AI security solutions. The company’s new AI products now account for 30% of total bookings, fueling growth in the competitive cyber...
Shares of Cre8 Enterprise Limited (CRE) surged nearly 165% after reporting a record 550 customers and a 482% rise in IPO filings in H1 2026. Abercrombie & Fitch (ANF) jumped over 35% following stronger-than-expected quarterly results and raised guida...
Greenland Mines Ltd. shares dropped nearly 50% after announcing a $20 million public offering, raising dilution concerns. Qfin Holdings saw an 18.9% decline following weaker Q2 revenue and sharply lower profits despite beating earnings expectations. ...
Olivia Nottebohm, Chief Operating Officer of Box, sold 5,834 shares of the company, generating $188,500 from the transaction. This insider sale could indicate personal financial planning or a shift in confidence, but without further context, its impa...
J.M. Smucker reported a strong first quarter with adjusted earnings of $3.24 per share, a 71% increase year-over-year, and revenue of $2.2 billion, beating analyst expectations. The company showed robust financial health with free cash flow of $337.3...
